Ajanta Pharma Ltd.
BSE: 532331 | Sector: Health care |
NSE: AJANTPHARM | ISIN Code: INE031B01049 |
BSE 00:00 | 16 May | 1683.60 |
-27.45 (-1.60%) |
OPEN
1884.40 |
HIGH
1884.40 |
LOW
1664.80 |
NSE 00:00 | 16 May | 1683.40 |
-29.65 (-1.73%) |
OPEN
1722.10 |
HIGH
1723.00 |
LOW
1661.55 |
OPEN | 1884.40 |
PREVIOUS CLOSE | 1711.05 |
VOLUME | 2918 |
52-Week high | 2420.00 |
52-Week low | 1593.30 |
P/E | 19.98 |
Mkt Cap.(Rs cr) | 14,378 |
Buy Price | 0.00 |
Buy Qty | 0.00 |
Sell Price | 0.00 |
Sell Qty | 0.00 |
Ajanta Pharma Ltd. (AJANTPHARM) - News Sector
-
USFDA rush after 2-year lull: 20-30% new products may be open to inspection
3.01 am | 16 May 2022 | Business Standard
The last two years saw limited physical inspections due to travel restrictions during the pandemic
-
A first in India: Zydus brings new drug for uncontrolled 'bad' cholesterol
12.04 am | 14 May 2022 | Business Standard
Uncontrolled LDL-c, which poses a major risk of cardiovascular diseases, lacked proper treatment despite patients' lifestyle changes and use of statin...
-
Cipla looks to invest more in mRNA tech; holds discussions with firms
2.03 am | 12 May 2022 | Business Standard
Speaking to Business Standard, Samina Hamied, executive vice chairperson, Cipla, says one must invest in research and development (R&D) to feed the co...
-
Cipla will use Covid-19 bulk drugs inventory when demand rises
11.46 pm | 11 May 2022 | Business Standard
The Covid-19 portfolio contributed 5-6 per cent of Cipla's turnover during peak Covid waves, the firm said
-
Bonus issue fails to lift Ajanta Pharma; stock hits 52-week low on weak Q4
12.27 pm | 11 May 2022 | Business Standard
In Q4FY22, Ajanta's earnings before interest, taxes, depreciation, and amortization declined 20 per cent year-on- year to Rs 207 crore.
-
Stocks to Watch: SBI, Cipla, Voda Idea, Gujarat Gas, Zensar, MGL, Welspun
8.11 am | 11 May 2022 | Business Standard
Stocks to Watch Today: The primary market too is likely to be abuzz with activity with three IPOs namely - Delhivery, Prudent Corporate Advisory Servi...
-
Cipla Q4 PAT dips 12% to Rs 362 cr owing to Covid inventory impact
2.26 am | 11 May 2022 | Business Standard
For the full fiscal, Cipla has posted a 4.7% jump in net profit to Rs 2,517 crore, revenue and Ebitda rose 13.6% and 6.4% respectively
-
Sun Pharma's Halol unit gets 10 observations under USFDA's Form 483
1.22 am | 11 May 2022 | Business Standard
Plant's OAI status is unchanged, hinting at status quo; Sun Pharma says will respond to observations within 15 days
-
Rainbow Medicare slumps 17% on debut in worst IPO listing in CY22 so far
11.10 pm | 10 May 2022 | Business Standard
Stock end at Rs 450, Rs 92 below issue price of Rs 542 a share
-
Rainbow Children's Medicare lists at 7% discount to issue price
10.30 am | 10 May 2022 | Business Standard
The stock listed at Rs 506, a 7% discount when compared with its issue price of Rs 542 per share on the BSE.
-
75% of Nifty50 stocks trade below 200-DMA; look weak on the charts
11.43 pm | 6 May 2022 | Business Standard
Tech Mahindra and Wipro have tumbled over 30 per cent, while Apollo Hospitals Enterprise and Dr. Reddy's Laboratories have plummeted 22 per cent so fa...
-
Sanofi India: Strong balance sheet, high cash reserves positives for stock
12.29 am | 6 May 2022 | Business Standard
Products in the price control list and growth of the non-power brand portfolio will be key monitorables
-
Pfizer sets up drug development centre at Chennai's IIT Research Park
9.34 am | 5 May 2022 | Business Standard
The centre integrates two essential functions under the export-oriented undertaking of Pfizer: Pharmaceutical Sciences (PharmSci) and Global Technolog...
-
Zomato, L&T Infotech, Solara, TTML plunge over 25% in one month
11.47 am | 4 May 2022 | Business Standard
Shares of Zomato hit a new low of Rs 64.70, down 7 per cent on the BSE in Wednesday's intra-day trade
-
Alembic Pharma posts Q4 net of Rs 35 cr as India and US businesses grow
7.02 pm | 2 May 2022 | Business Standard
During the quarter, Alembic Pharma's US portfolio strengthened with the acquisition of the balance 40 per cent stake in Aleor Dermaceuticals
-
Solara Active Pharma slips 15% after Rajender Rao resigns as MD & CEO
11.21 am | 2 May 2022 | Business Standard
Jitesh Devendra, former CEO and Managing Director (MD) of the company will return to Solara as MD, to steer the reset strategy of the Company
-
Gland Pharma advances 9% on heavy volumes; stock hits 9-week high
12.18 pm | 21 Apr 2022 | Business Standard
At 09:15 AM; around 5.42 million equity shares, representing 3.3 per cent of total equity of Gland Pharma, changed hands on the BSE
-
Cost pressure likely to weigh on pharma companies' margins in Q4
12.50 am | 20 Apr 2022 | Business Standard
Among Indian firms, Edelweiss feels that Cipla (respiratory) and Sun Pharma (specialty) are better placed to tide the price erosion
-
Growth trajectory, margins anc client additions to sustain for Laurus Labs
10.49 pm | 19 Apr 2022 | Business Standard
Some of the growth is captured in the price rally, higher valuations
-
Sanofi India names Rodolfo Hrosz managing director effective June 1
6.58 pm | 18 Apr 2022 | Business Standard
He will transition from being Sanofi's GM, Consumer Healthcare business in Brazil to the new role in India as soon as regulatory approvals are in plac...
Quick Links for Ajanta Pharma:
-
News
Announcements Brokerage Reports Business Earnings Sector -
Corporate Action
AGM Board Meetings Bonus Dividends EGM Rights Split -
INFORMATION
Bulk Deals Company History MF Holding Listing Info Locations Shareholding -
Financials
Financial Overview Balance Sheet Profit & Loss Cash Flow Ratios Quarterly Results Half Yearly Results Nine Monthly Results Yearly Results -
Annual Report
Auditors Report Chairman's Speech Company Management Directors' Report Finished Goods Raw Materials -
Peer Comparison
Competition Market Cap Price Price Performance Net Sales Net Profit Total Assets Historical Prices